Overview
Product nameHepatitis C Virus Core 6a protein
Protein descriptionRecombinant fragment, corresponding to N terminal amino acids 2-119 of Hepatitis C Virus Core protein, genotype 6a, containing the Hepatitis C Virus core nucleocapsid immunodominant regions.
Expression hostE. coli
Properties
Purity> 95
% by SDS-PAGE
Purification notesHepatitis C Virus Core 6a protein was purified by a proprietary chromatographic technique.
Biological activityThis protein is immunoreactive with sera of Hepatitis C Virus-infected individuals.
FormLiquid
Storage instructionsShipped at 4°C. Upon delivery aliquot and store at -20°C. Avoid freeze / thaw cycles.
Storage bufferPreservative: None
Constituents: 50% Glycerol, 60mM Sodium chloride, 50mM Tris HCl, 10mM Glutathione, 0.25% sarkosyl, pH 8.0
Concentration information loading...
Research Areas
Applications
Our Abpromise guarantee covers the use of
ab67734
in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
|
Application
|
Notes |
| WB |
WB: Use at an assay dependent dilution. Predicted molecular weight: 14 kDa. |
| ELISA |
ELISA: Use at an assay dependent dilution. |
Protein info
-
Alternative names
HCV 6aHCV core 6aHCV core genotype 6a
HCV6aHepatitis C Virus core genotype 6a
see all
RelevanceHCV (Hepatitis C Virus) viral core protein forms the internal viral coat that encapsidates the genomic RNA and is enveloped in a host cell-derived lipid membrane. The hepatitis C virus (HCV) core protein represents the first 177 amino acids of the viral precursor polyprotein and is cotranslationally inserted into the membrane of the endoplasmic reticulum. The N terminus of the core protein is involved in transcriptional repression.
There are over 20 different subtypes of Hepatitis C Virus; the preponderance and distribution of HCV genotypes varies globally. HCV genotype 6a is found in a restricted part of South East Asia, including Hong Kong, Macau and Vietnam. HCV Genotype information is important because of the role it plays in predicting HCV medical treatment response and treatment duration. Sustained cure rates (sustained viral response) of 75% or better occur in people with genotypes HCV 2 and 3 in 24 weeks of treatment. Genotypes 1a and 1b, the most prevalent worldwide, have the poorest rates of response to the present treatment regimen, which is a combination of pegylated alfa interferon 2b with ribavirin.
HCV core protein is among the most conserved proteins in HCV and is known to induce sensitization of cytotoxic T lymphocytes (CTL). Therefore, it is a prime candidate for a component of a potential HCV vaccine.
References for Hepatitis C Virus Core 6a protein (ab67734)
ab67734
has not yet been referenced specifically in any publications.
Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"
